Renal Cell Carcinoma

>

Latest News

Unique Challenges of Using IO/TKI Combinations in Metastatic RCC
Unique Challenges of Using IO/TKI Combinations in Metastatic RCC

March 12th 2024

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, asked participants to share their experiences using nivolumab plus cabozantinib in patients with advanced renal cell carcinoma. This is the second of 2 articles based on this event.

Evolving Evidence Guides Treatment Selection for Favorable-Risk mRCC
Evolving Evidence Guides Treatment Selection for Favorable-Risk mRCC

March 6th 2024

Microbiome Impact and Promising Clinical Outcomes for Renal Cell Carcinoma
Microbiome Impact and Promising Clinical Outcomes for Renal Cell Carcinoma

March 3rd 2024

Guideline Recommendation Favors Doublet Over Triplet Therapy in ccRCC
Guideline Recommendation Favors Doublet Over Triplet Therapy in ccRCC

February 28th 2024

Risk Groups Vital to Interpreting Results of RCC Immunotherapy Trials
Risk Groups Vital to Interpreting Results of RCC Immunotherapy Trials

February 21st 2024

Video Series
Video Interviews
Podcasts

More News